Testimonials
Testimonials
"The timelines were very short and I have never worked with staff from another agency that were willing to work as hard on an assignment as the HERON consultants."
Marketing Manager, UK Pharmaceutical Company
"We have found HERON Evidence Development to be the best supplier of systematic reviews."
Evidence Based Medicine Manager, US Pharmaceutical Company
"Thanks for your great help in the total process!"
Director, European Affiliate Pharmaceutical Company
"I was very impressed with your expertise and support. I will be contacting in the future."
Director, Global Health Economics and Reimbursement
"Many thanks for all your hard work on this literature review.
**** Thanks again for sterling job on the review****"
Health Outcomes Manager, Top 10 Pharmaceutical Company
"I think we're still reeling from all the positive feedback!"
Director, Europe Devices
"Thank you! You and your team have done fabulous work."
Manager, Health Economics and Pricing
"I was very impressed with the set-up of the dossier. I think this will work well with our local markets!"
Director, Health Economics and Reimbursement
"it has been an absolute pleasure working with you. Thank you for your excellent, hard work in putting these dossiers together. I look forward to the opportunity to work with HERON again in the future."
Executive Director, Reimbursement
"We chose HERON after an extensive review process, confident that we were placing the future of Tysabri in the UK in very safe hands. On behalf of everyone who is affected by this debilitating disease, we are delighted by the outcome of this appraisal, and know that it was the innovative approach and sheer hard work from the entire team that clearly demonstrated the benefits of Tysabri and led to the successful outcome of the appraisal."
Head of Sales and Marketing
"Congratulations to you and your teams on a great result from the NICE submission efforts. This will have an impact beyond the shores of England and Wales."
Global Head of Health Economics
"This definitely would have a far reaching impact for patient access to Tysabri and may have wider implications for technology assessments of all chronic and debilitating diseases."
Health Economist, Top 10 Pharmaceutical Company
"CONGRATULATIONS!!! Seems that all of your work was well invested! This is also very beneficial for the German situation."
Head of Health Economics, Top 10 Pharmaceutical Company